Join
Live feed
·
PRReleasevia Quantisnow
Neurocrine Biosciences Inc. logo

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026

ByQuantisnow·Wall Street's wire, on your screen.
NBIX· Neurocrine Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NBIX (Neurocrine Biosciences Inc.) and more on Quantisnow.